Microbicide Trial Three-Arm Design May Be Optimal Initially – Panelists
This article was originally published in The Tan Sheet
Executive Summary
A microbicide clinical trial "win" should be based on "compelling" evidence of superior efficacy versus placebo and "supportive" evidence compared with a no-treatment arm, FDA Antiviral Drugs Advisory Committee consultant Richard Haubrich, MD, University of California, San Diego, said at an Aug. 20 meeting of the panel